VIDEO: Sacituzumab govitecan combo improves survival in triple-negative breast cancer

CHICAGO — In this video, Megan Kruse, MD, breast medical oncologist at Cleveland Clinic, discusses primary results from ASCENT-04 evaluating sacituzumab govitecan plus pembrolizumab in metastatic triple-negative PD-L1-positive breast cancer.The findings of the phase 3 trial, presented at ASCO Annual Meeting, showed significant improvement in PFS with sacituzumab govitecan (Trodelvy, Gilead